Thrombotic vessel occlusion in the brain causes acute hypoxia in the respective vascular territory and subsequently induces neuronal death in the core and the penumbra of the ischemic lesion which is caused by necrosis and apoptosis.
Thrombotic vessel occlusion in the brain causes acute hypoxia in the respective vascular territory and subsequently induces neuronal death in the core and the penumbra of the ischemic lesion which is caused by necrosis and apoptosis. 1, 2 The anti-apoptotic protein bcl-2 is known to protect most eukaryotic cells from apoptotic or necrotic cell death. 3 Bcl-2 also protects human neurons in cell culture against apoptosis induced by withdrawal of nerve growth factor (NGF) and by amyloid ␤-peptide, as well as against oxidative and hypoxic insults. [4] [5] [6] Delivery of the bcl-2 gene and expression of transgenic bcl-2 in ischemic brain tissue results in neuroprotection and may inhibit hypoxic cell death in vivo. [7] [8] [9] [10] Most of the previous studies on neuroprotective gene transfer used genetically engineered virus vectors, such as herpes-simplex type I virus (HSV), adenovirus (AV), or adeno-associated virus (AAV). 8, 9, 11 Cationic liposomes condense DNA and introduce it into cells by membrane fusion and endocytosis. Furthermore, liposomes may transiently introduce DNA and express transgenes even in postmitotic, non-dividing cells including neurons. 13 We have recently shown that postmitotic human neurons may be efficiently transfected by lipoplexes. 6 Hypoxia-inducible transgene expression was also demonstrated in cultured hypoxic neurons. Furthermore, transfection with liposomes carrying the human bcl-2 gene protected cultured neurons against hypoxic cell death. In the present study, the cationic liposome preparation DOTAP (Boeringer Mannheim, Mannheim, Germany) was employed for transferring the human bcl-2 gene into ischemic brain in an animal model of focal cerebral ischemia. DOTAP liposomes have been used as a gene delivery system in a number of in vivo appli- cations. 12, 14, 15 It has been shown that DOTAP is more efficient than LipofectAmine (Gibco BRL, Berlin, Germany) for gene transfer in lung and in cultured neurons. 6, 12 In the present study, the therapeutic transgene bcl-2 complexed with DOTAP liposomes was delivered to the brain by means of a single intrathecal injection.
Recently, new hypoxia-responsive vectors for tumorspecific gene therapy have been developed. Constructs containing five copies of hypoxia-responsive elements (HRE) derived from the 5'-untranslated region of the human vascular endothelial growth factor gene (VEGF)
showed excellent transcriptional activation at low oxygen concentrations. 16 The combination of HRE with a CMV minimal promoter exhibited excellent hypoxia responsiveness with over 500-fold induction in some cell types. Previous studies demonstrated efficient VEGF promotermediated induction of transgene expression in hypoxic human neurons in culture. 6 The present study employed two different types of bcl-2 expression cassettes in two different plasmid vectors: one driven by the strong constitutive cytomegalovirus promoter (pCMV) and another based on the hypoxia-inducible VEGF promoter (pHRE). 6 The expression plasmids pCMV-bcl2 and pHRE-bcl2 could be efficiently transfected into rat brain in vivo. Lipoplexes were injected intrathecally immediately after occlusion of the middle cerebral artery (MCA). Intrathecal injection of lipoplexes or liposomes alone into the CSF did not cause morbidity or mortality in the experimental animals, both in terms of general or specific neurological toxicity. No pathological morphology was discovered in brain removed from treated animals (data not shown). Ischemic brain transfected with pCMV-bcl2 expressed the transgene protein at high levels in cortical areas and in white matter, as shown by bcl-2 immunostaining ( Figure  1a) . The liposome control group showed essentially no bcl-2 immunostaining (Figure 1b ), which suggests that the level of endogenous bcl-2 expression in brain cells in this animal model was very low and essentially beyond detection by the technique used. Animals treated with the pHRE-bcl2 vector showed intermediate to low intensity of bcl-2 immunostaining limited to the ischemic area (data not shown). In general, pHRE-bcl2 transfection resulted in weaker but more damage-selective protein expression compared with pCMV-bcl2.
Ischemic regions in the brain were visualised by triphenyltetrazolium chloride (TTC) staining (Figure 1c) . TUNEL-positive cells were quantified per microscopic visual field, which at the chosen magnification of ×240 had a length of 100 m. Penumbra was defined as the part of the TTC-stained area immediately adjacent to normal (non-stained) brain tissue. Treatment of animals with intrathecal DOTAP/pCMV-bcl2 lipoplexes, but not with DOTAP/pHRE-bcl2 lipoplexes was able to significantly reduce the volume of the infarct regions, which was 109 ± 8 mm 3 for pCMV-bcl2, 152 ± 29 mm 3 for pHRE-bcl2, and 155 ± 18 mm 3 for control animals ( Figure 2a ). Brain of bcl-2-transfected animals showed a significant reduction of apoptotic cells in the TTC-stained infarct and penumbra area compared with the mock-transfected control rats. The number of apoptotic cells was reduced to 66% of control in the pHRE-bcl2 transfected group and to 37% of control for pCMV-bcl2 transfected rats (Figure 2b) .
Transient focal cerebral ischemia and reperfusion injury initiate a cascade of molecular events leading to apoptosis and eventually to neuronal cell death. Therefore, anti-apoptotic therapeutic strategies have been intensively investigated as a means for protection against postischemic neuronal loss. Bcl-2 is known to prevent most forms of apoptotic or necrotic cell death. It has been previously shown that the bcl-2 protein has neuroprotective functions and may inhibit in culture and in vivo postischemic cell death. [7] [8] [9] [10] Most of these studies, however, used genetically engineered virus vectors. Besides the potentially higher biological risk through the transfer of virus genes not necessary for the treatment, there is a possibility of permanent integration and expression of transgenic bcl-2 in neuronal, glial, and endothelial cells in the CNS. Since bcl-2 is overexpressed in many human tumors 17 and in tumor vasculature, 18 the integrating virus vector approach may be associated with the long-term oncogenic potential of the treatment.
On the other hand, as lipoplexes do not integrate in the genome of target cells, and transgenic expression from plasmid vectors is turned off after a few weeks, 19 lipoplex-mediated bcl-2 gene transfer immediately after an acute ischemic infarct in the brain with elimination of the transgene after the anti-apoptotic protection has taken place may be a low-risk and clinically useful strategy for neuroprotection.
In this work we employed liposome-mediated bcl-2 gene transfer to treat transient focal cerebral ischemia in an animal model. The liposome-mediated expression of bcl-2 was able to significantly reduce the infarct volume, although this difference was seen with the constitutive expression from the CMV promoter only, and may depend on the level of expression of the transgene. Bcl-2 expression from the pCMV-bcl2 vector reduced apoptosis in the infarct and penumbra area to 37% of the corresponding value in control animals (100%).
Previous bcl-2 gene transfer for neuroprotection after cerebral ischemia was carried out by means of direct injection of the respective viral vector into the affected area of the brain. Intraventricular administration was also shown to be effective. Intraventricular administration of AV vectors carrying the interleukin-1 receptor antagonist (IL-1ra) gene into mice or rats leads to overexpression of IL-1ra protein in the focally ischemic rodent brain and to reduction of infarct volume. 11, 20 However, both intraventricular and direct intracerebral injection are invasive surgical procedures and may inflict additional trauma and injury to the brain. Direct intrathecal injection into the cisterna magna on the other hand, as used in our study, offers easy access to the intracranial CSF space and is usually carried out in a fully conscious and non-anesthetized patient. Thus, this procedure seems to be less invasive and easier to perform, and offers a more global access of vector to the CNS. Several studies have shown that gene transfer to the brain by intrathecal injection of vecGene Therapy tors may be efficient and may take part in different compartments. [21] [22] [23] AV vectors carrying the ␤-galactosidase gene were injected into rat CSF and produced transgene expression in cerebral blood vessels and perivasucular tissue. 21 Meuli-Simmen et al 23 have achieved liposomemediated gene transfer to mouse brain by intrathecal administration. Intrathecal injection of lipoplexes containing the chloramphenicol acetyltransferase (CAT) reporter gene showed that CAT activity in the brain reached peak levels between 24 h and 1 week after injection, and was still present as traces 3 weeks after a single injection. Liposome-mediated intrathecal gene transfer of the human granulocyte colony-stimulating factor (hG-CSF) gene produced high levels of hG-CSF activity in both the brain and the spinal cord.
In the present study, we employed intrathecal injection of lipoplexes for delivery of the bcl-2 gene to ischemic rat brain. Immunohistochemical staining for bcl-2 after pCMV-bcl2 transfection showed abundant bcl-2 expression in neuronal and glial cells in cortical and deep subcortical areas, in meninges, and on the CSF surface of vessels. These findings indicate that the intrathecal administration of lipoplexes may result in significant and ubiquitous constitutive expression of a therapeutic transgenic protein within the CNS. Recently, Hayashi et al 24 used liposomes for in vivo gene transfer of hepatocyte growth factor (HGF) to the subarachnoid space of gerbils by intrathecal infusion. These authors demonstrated gene transfer in the cerebral cortex, in the hippocampus and in the choroid plexus. Transfer and expression of HGF was sufficient to reduce delayed neuronal death, and in this HGF gene transfer was more effective than administration of recombinant HGF. 24 Moreover, liposomemediated gene transfer of the nerve growth factor (NGF) was shown to attenuate loss of cholinergic neurons in the rat septum after traumatic brain injury. 13 We reported recently that hypoxia-inducible plasmid vectors transduced by liposomes in neuronal cells in culture may result in efficient transgene expression. 6 Hypoxic treatment was able to induce marker gene expression 34-fold in NT2 cells and four-fold in NT2N neurons. Hypoxia-induced expression of the anti-apoptotic protein bcl-2 in hypoxic NT2N neurons significantly inhibited apoptosis. Other groups have also demonstrated hypoxia-inducible transgene expression in culture and in vivo in ischemic myocardial cells using HRE from the human erythropoietin promoter. 25 In our present study, the hypoxia-inducible expression vector pHRE-bcl2 based on the VEGF promoter 16 was employed along with a constitutively expressing vector based on the CMV promoter for liposome-mediated transfection of ischemic brain in vivo. pHRE-bcl2-treated animals showed no significant decrease in infarct volume as compared with controls. Immunohistochemistry showed relatively low expression of bcl-2, which was in addition, limited to the area of infarct and penumbra. On the other hand, the level of expression of bcl-2 achieved by the pHRE-bcl2 construct was sufficient to significantly inhibit apoptotic cell death induced by ischemia.
In conclusion, lipoplex-mediated transient transfer of the bcl-2 gene has a neuroprotective effect in this rat model of focal cerebral ischemia. While constitutive expression of the bcl2-protein results in higher protein levels and ubiquitous distribution of transgene expression, hypoxia-inducible vectors have the advantage of limiting the gene transfer to the hypoxic damage area only and thus of limiting late biological risks. This strategy needs to be further optimized in animal models in order to achieve higher levels of hypoxia-inducible bcl-2 protein expression and to investigate long-term effects of the treatment.
